

## **Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)**

*Sujoy Ghosh, et al. Diabetes Ther (2020) 11:2257–2268.*

- 10,623 patient's retrospective data from 18 centres across the country was collated.
- At 12 weeks after initiation of teneligliptin as monotherapy or add-on to other medications (combination therapy), the patients showed a significant decrease from baseline in mean HbA1c, FPG and PPG.
- Mean HbA1c dropped from  $8.66 \pm 1.15\%$  at baseline to  $7.67 \pm 1.28\%$  at 12 weeks. The mean reductions in FPG and PPG were 43.12mg/dL and 87.73 mg/dL respectively.

**Teneligliptin significantly improved glycaemic parameters in Indian patient's with T2DM when prescribed either as monotherapy or as an add-on therapies as well.**